Every Form 4 that INmune Bio Inc. (INMB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INMB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INMB filings page.
Inmune Bio, Inc. director Juda Scott exercised common stock purchase warrants in a cash transaction, acquiring 14,801 shares of Common Stock at $1.40 per share. This exercise stems from an April 2024 warrant inducement agreement with the company.
Following the transaction, Scott directly owns 86,404 shares of Common Stock. Under the same inducement letter, the maturity date of the remaining 50% of Scott’s April 2024 warrants that were not exercised was extended from June 30, 2026 to December 31, 2027, providing a longer exercise window for those warrants.
INmune Bio, Inc. Chief Scientific Officer Mark William Lowdell exercised common stock purchase warrants to acquire 7,211 shares of Common Stock at an exercise price of $1.40 per share. This increased his directly held stake to 1,518,017 Common shares.
The exercise was part of a warrant inducement arrangement tied to April 2024 Warrants. Lowdell agreed to exercise 50% of his April 2024 Warrants for cash, while the company extended the maturity date of the remaining 50% of those warrants from June 30, 2026 to December 31, 2027.
Inmune Bio, Inc. Chief Executive Officer David J. Moss exercised common stock purchase warrants to acquire 9,014 shares of Common Stock at an exercise price of $1.40 per share in cash. Following this transaction, he directly holds 1,294,883 shares of Common Stock. Under a related warrant inducement offer letter, the remaining 50% of his April 2024 Warrants that were not exercised now have their maturity date extended to December 31, 2027.
Inmune Bio, Inc. (INMB) reported a stock option repricing for a director effective as of November 18, 2025. Stockholders approved a one-time adjustment that reduced the exercise price of certain outstanding stock options granted under the company’s 2017, 2019 and 2021 stock incentive plans to $1.50 per share, matching the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on that date. The filing shows multiple stock option awards where higher exercise prices were replaced by new options at $1.50, while all other terms, including vesting schedules and expiration dates, remain unchanged and continue to depend on the director’s ongoing service.
Inmune Bio, Inc. (INMB) reported that its Chief Executive Officer and director had multiple outstanding stock option awards repriced on November 18, 2025. Stockholders approved a one-time repricing of certain options granted under the company’s 2017, 2019, and Second Amended and Restated 2021 Stock Incentive Plans, reducing the exercise price of each affected option to $1.50, which was the company’s Nasdaq closing share price on the repricing date. For example, one stock option covering 400,000 shares originally exercisable at $7.80 was adjusted to a $1.50 exercise price. The filing states that all other terms of these repriced options, including vesting schedules and terms, remain unchanged, and exercisability continues to depend on the CEO’s ongoing service.
Inmune Bio (INMB) reported a Form 4 filing for its Chief Scientific Officer, Mark William Lowdell, reflecting a one-time repricing of certain outstanding stock options. Effective as of November 18, 2025, stockholders approved reducing the exercise price of these options granted under the 2017, 2019 and Second Amended and Restated 2021 Stock Incentive Plans to $1.50, equal to the Nasdaq Capital Market closing price of the company’s common stock on that date. The table shows multiple existing stock option grants being adjusted from higher exercise prices to $1.50 while keeping the same share amounts and expiration dates. All other terms, including vesting and option terms, remain in full force and effect, so the change mainly affects the price at which these options can be exercised.
Inmune Bio, Inc. (INMB) reported a one-time repricing of certain outstanding stock options for a company director effective November 18, 2025. The stockholders approved reducing the exercise price of these existing options to $1.50 per share, which matches the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on that date. Multiple previously granted stock options with higher exercise prices, covering blocks such as 108,000, 35,000, 32,500 and other share amounts, were cancelled and replaced with new options for the same number of underlying common shares at the new $1.50 exercise price. All other terms of the repriced options, including vesting schedules and expiration dates under the company’s 2017, 2019 and 2021 stock incentive plans, remain unchanged.
Inmune Bio, Inc. (INMB) director reprices stock options following shareholder approval. On November 18, 2025, the company’s stockholders approved a one-time repricing of certain outstanding stock options granted under Inmune Bio’s 2017, 2019 and 2021 stock incentive plans. The repricing reduced the per-share exercise price of each affected option to $1.50, which was the closing price of Inmune Bio common stock on The Nasdaq Capital Market on the repricing date. The table shows prior options with exercise prices such as $7.80, $3.91, $24.82, $17.49, and others being replaced with new options at $1.50 for the same share amounts, including grants of 108,000 and 35,000 shares. All other terms of these options, including vesting schedules and expiration dates, remain unchanged and continue to depend on the director’s ongoing service.
Inmune Bio, Inc. (INMB) reported a change in the stock options held by its interim CFO, Cory Randall Ellspermann. On November 18, 2025, shareholders approved a one-time repricing of certain outstanding options granted under the company’s 2017, 2019 and 2021 stock incentive plans. The repricing reduced the exercise price of each affected option to $1.50 per share, which was the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on that date.
The Form 4 shows cancellations of existing stock options with higher exercise prices and the grant of replacement options at the new $1.50 exercise price for the same numbers of underlying shares and original expiration dates. All other terms of these options, including vesting schedules and overall terms, remain unchanged and continue to depend on the executive’s ongoing service with the company.
Inmune Bio, Inc. (INMB) director Marcia Allen reported a repricing of her stock options, following stockholder approval effective November 18, 2025. Certain existing options granted under the company’s 2017, 2019 and 2021 stock incentive plans had their exercise price reduced to $1.50 per share, matching the Nasdaq closing price of Inmune Bio’s common stock on the repricing date. The filing shows prior options with higher exercise prices, including awards at $3.91, $7.92, $9.74, $17.49, $24.82 and $5.05, being adjusted so that the same numbers of underlying shares remain, but at the new exercise price. All other terms of these options, such as vesting schedules and expiration dates, remain unchanged, and the awards continue to be tied to Allen’s ongoing service with the company.